Skip to main content

Advertisement

SpringerLink
Log in

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy

  • Laboratory Investigation - Human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) inhibit anti-tumor immune responses and facilitate tumor growth. Precursors for these immune cell populations migrate to the tumor site in response to tumor secretion of chemokines, such as monocyte chemoattractant protein-1 (MCP-1/CCL2), which was originally purified and identified from human gliomas. In syngeneic mouse GL261 glioma and human U87 glioma xenograft models, we evaluated the efficacy of systemic CCL2 blockade by monoclonal antibodies (mAb) targeting mouse and/or human CCL2. Intraperitoneal (i.p.) administration of anti-mouse CCL2 mAb as monotherapy (2 mg/kg/dose, twice a week) significantly, albeit modestly, prolonged the survival of C57BL/6 mice bearing intracranial GL261 glioma (P = 0.0033), which was concomitant with a decrease in TAMs and MDSCs in the tumor microenvironment. Similarly, survival was modestly prolonged in severe combined immunodeficiency mice bearing intracranial human U87 glioma xenografts treated with both anti-human CCL2 mAb and anti-mouse CCL2 antibodies (2 mg/kg/dose for each, twice a week) compared to mice treated with control IgG (P = 0.0159). Furthermore, i.p. administration of anti-mouse CCL2 antibody in combination with temozolomide (TMZ) significantly prolonged the survival of C57BL/6 mice bearing GL261 glioma with 8 of 10 treated mice surviving longer than 70 days, while only 3 of 10 mice treated with TMZ and isotype IgG survived longer than 70 days (P = 0.0359). These observations provide support for development of mAb-based CCL2 blockade strategies in combination with the current standard TMZ-based chemotherapy for treatment of malignant gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

BIL:

Brain infiltrating lymphocyte

CNS:

Central nervous system

mAb:

Monoclonal antibody

References

  1. Mizutani K, Sud S, McGregor NA et al (2009) The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11:1235–1242

    PubMed  CAS  Google Scholar 

  2. Huang B, Lei Z, Zhao J et al (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252:86–92

    Article  PubMed  CAS  Google Scholar 

  3. Vanderkerken K, Vande BI, Eizirik DL et al (2002) Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 19:87–90

    Article  PubMed  CAS  Google Scholar 

  4. Ohta M, Kitadai Y, Tanaka S et al (2002) Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 102:220–224

    Article  PubMed  CAS  Google Scholar 

  5. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N (1998) Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194:335–340

    PubMed  CAS  Google Scholar 

  6. Lebrecht A, Grimm C, Lantzsch T et al (2004) Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 25:14–17

    Article  PubMed  CAS  Google Scholar 

  7. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ (2007) CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9:556–562

    Article  PubMed  CAS  Google Scholar 

  8. Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727–740

    Article  PubMed  CAS  Google Scholar 

  9. Sweet MJ, Campbell CC, Sester DP et al (2002) Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages. J Immunol 168:392–399

    PubMed  CAS  Google Scholar 

  10. Scholl SM, Pallud C, Beuvon F et al (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86:120–126

    Article  PubMed  CAS  Google Scholar 

  11. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174

    Article  PubMed  CAS  Google Scholar 

  12. Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26:373–400

    Article  PubMed  Google Scholar 

  13. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59(10):1593–1600

    Article  PubMed  Google Scholar 

  14. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ (1989) Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 169:1449–1459

    Article  PubMed  CAS  Google Scholar 

  15. Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ (1989) Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol 142:1956–1962

    PubMed  CAS  Google Scholar 

  16. Graeber MB, Scheithauer BW, Kreutzberg GW (2002) Microglia in brain tumors. GLIA 40:252–259

    Article  PubMed  Google Scholar 

  17. Takeshima H, Kuratsu J, Takeya M, Yoshimura T, Ushio Y (1994) Expression and localization of messenger RNA and protein for monocyte chemoattractant protein-1 in human malignant glioma. J Neurosurg 80:1056–1062

    Article  PubMed  CAS  Google Scholar 

  18. Desbaillets I, Tada M, De Tribolet N, Diserens AC, Hamou MF, Van Meir EG (1994) Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer 58:240–247

    Article  PubMed  CAS  Google Scholar 

  19. Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST (1997) Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol (Berl) 93:518–527

    Article  CAS  Google Scholar 

  20. Jordan JT, Sun W, Hussain SF, Deangulo G, Prabhu SS, Heimberger AB (2008) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57:123–131

    Article  PubMed  CAS  Google Scholar 

  21. Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, Ushio Y (1993) Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst 85:9–1836

    Article  Google Scholar 

  22. Platten M, Kretz A, Naumann U et al (2003) Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 54:388–392

    Article  PubMed  CAS  Google Scholar 

  23. Loberg RD, Ying C, Craig M et al (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67:9417–9424

    Article  PubMed  CAS  Google Scholar 

  24. Tsui P, Das A, Whitaker B et al (2007) Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies. Hum Antibodies 16:117–125

    PubMed  CAS  Google Scholar 

  25. Carton JM, Sauerwald T, Hawley-Nelson P et al (2007) Codon engineering for improved antibody expression in mammalian cells. Protein Expr Purif 55:279–286

    Article  PubMed  CAS  Google Scholar 

  26. Fujita M, Zhu X, Sasaki K et al (2008) Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 180:2089–2098

    PubMed  CAS  Google Scholar 

  27. Nishimura F, Dusak JE, Eguchi J et al (2006) Adoptive transfer of Type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 66:4478–4487

    Article  PubMed  CAS  Google Scholar 

  28. Sasaki K, Zhu X, Vasquez C et al (2007) Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 67:6451–6458

    Article  PubMed  CAS  Google Scholar 

  29. Zhu X, Nishimura F, Sasaki K et al (2007) Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 5:10

    Article  PubMed  Google Scholar 

  30. Zhu X, Fallert-Junecko BA, Fujita M et al (2010) Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 59:1401–1409

    Article  PubMed  CAS  Google Scholar 

  31. Lewis C, Murdoch C (2005) Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 167:627–635

    Article  PubMed  CAS  Google Scholar 

  32. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG (2004) Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 70:229–243

    Article  PubMed  Google Scholar 

  33. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7:134–153

    Article  PubMed  CAS  Google Scholar 

  34. Stupp R, Dietrich PY, Ostermann KS et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382

    Article  PubMed  CAS  Google Scholar 

  35. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  36. Ueda R, Fujita M, Zhu X et al (2009) Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 15:6551–6559

    Article  PubMed  CAS  Google Scholar 

  37. Fridlender ZG, Buchlis G, Kapoor V et al (2010) CCL2 blockade augments cancer immunotherapy. Cancer Res 70:109–118

    Article  PubMed  CAS  Google Scholar 

  38. Ford AL, Goodsall AL, Hickey WF, Sedgwick JD (1995) Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4 + T cells compared. J Immunol 154:4309–4321

    PubMed  CAS  Google Scholar 

  39. Badie B, Schartner J (2001) Role of microglia in glioma biology. Microsc Res Tech 54:106–113

    Article  PubMed  CAS  Google Scholar 

  40. Okada H, Kohanbash G, Zhu X et al (2009) Immunotherapeutic approaches for glioma. Crit Rev Immunol 29:1–42

    PubMed  CAS  Google Scholar 

  41. Fujita M, Scheurer ME, Decker SA et al (2010) Role of type 1 IFNs in antiglioma immunosurveillance–using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res 16:3409–3419

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Research Funding Agreement with Centocor, Inc.; the National Institute of Health (NIH; 1R01NS055140, 2P01NS40923, and 1P01CA132714).

Author information

Authors and Affiliations

  1. Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Xinmei Zhu, Mitsugu Fujita & Hideho Okada

  2. Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

    Xinmei Zhu, Mitsugu Fujita & Hideho Okada

  3. Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Hideho Okada

  4. Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Hideho Okada

  5. Ortho Biotech Oncology Research and Development, Centocor, Inc, Radnor, PA, USA

    Linda A. Snyder

  6. G12a Research Pavilion at Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA, 15213, USA

    Hideho Okada

Authors
  1. Xinmei Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsugu Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda A. Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideho Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideho Okada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhu, X., Fujita, M., Snyder, L.A. et al. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 104, 83–92 (2011). https://doi.org/10.1007/s11060-010-0473-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0473-5

Keywords

Search

Navigation